FindTrial
Sign In

CART 19

BIOLOGICAL3 trials

Sponsors

University of Pennsylvania

Conditions

LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)Leukemia, Acute LymphoblasticLymphoblastic Leukemia, Acute, Childhood

Early Phase 1

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
TerminatedNCT02640209
University of PennsylvaniaLYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Start: 2016-01-29End: 2019-07-16Updated: 2023-06-22

Phase 1

Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
CompletedNCT02906371
University of PennsylvaniaLymphoblastic Leukemia, Acute, Childhood
Start: 2016-08-31End: 2021-06-30Updated: 2021-07-02

Phase 2

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
TerminatedNCT02935543
University of PennsylvaniaLeukemia, Acute Lymphoblastic
Start: 2016-10-31End: 2018-12-12Updated: 2023-06-22

Related Papers

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function
Blood2024-11-052 citations
Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123
Blood2024-11-051 citations
Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy
Blood2024-11-051 citations
In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing
Blood2024-11-051 citations
Abstract B051: Marrow and peripheral blood cytokine architecture differences between pediatric patients receiving CD19- and CD22-directed CART
Cancer Research2024-09-05
IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22
Blood2023-11-02
229 Large-scale omics profiling reveals type-2 functionality sustaining 8-year leukemia remission following CAR T cell therapy
Regular and Young Investigator Award Abstracts2023-10-31
Impact of socioeconomic status on survival after CD19 CART therapy.
Journal of Clinical Oncology2022-06-01
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
Blood Advances2022-03-29115 citations
Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Blood2021-11-0518 citations
CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome
Blood2021-11-0516 citations
Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL
Blood2021-11-053 citations
Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19
Blood2021-11-051 citations
Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells
Blood2020-11-049 citations
CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).
Journal of Clinical Oncology2020-05-2018 citations
Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Biology of Blood and Marrow Transplantation2020-01-2315 citations
Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy
Blood2019-11-1311 citations
Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019
Blood2019-11-133 citations
Acute Kidney Injury after Chimeric Antigen Receptor T-Cell Therapy for Pediatric Acute Lymphoblastic Leukemia
Biology of Blood and Marrow Transplantation2019-01-3111 citations
CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia
Blood2018-11-2912 citations

3 more papers not shown